主要文件

查看所有文档

R0908

R1881

Name: R1881
Brand: SIGMA

≥98% (HPLC), Androgen receptor agonist, powder

别名:

(17b)-17-羟基-17-甲基-雌甾-4,9,11-三烯-3-酮, NSC 92858, RU 1881, 甲基群勃龙, 美曲勃龙

登录查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:

C₁₉H₂₄O₂

化学文摘社编号:

965-93-5

分子量:

284.39

UNSPSC Code:

51111800

PubChem Substance ID:

329823993

NACRES:

NA.77

MDL number:

MFCD00199021

Assay:

≥98% (HPLC)

Form:

powder

Quality level:

100

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

属性

产品名称

R1881, ≥98% (HPLC)

Quality Level

100

assay

≥98% (HPLC)

form

powder

optical activity

[α]/D -48 to -68°

drug control

USDEA Schedule IIIN; Home Office Schedule 4.2; regulated under CDSA - not available from Sigma-Aldrich Canada

color

light yellow to yellow

solubility

DMSO: ≥10 mg/mL

storage temp.

2-8°C

SMILES string

C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3C=C[C@]12C

InChI

1S/C19H24O2/c1-18-9-7-15-14-6-4-13(20)11-12(14)3-5-16(15)17(18)8-10-19(18,2)21/h7,9,11,16-17,21H,3-6,8,10H2,1-2H3/t16-,17+,18+,19+/m1/s1

InChI key

CCCIJQPRIXGQOE-XWSJACJDSA-N

说明

Biochem/physiol Actions

R1881（美曲勃龙）是一种强效的合成雄激素。

雄激素受体（AR）是核激素受体/转录因子。 R1881，也称美曲勃龙，是一种合成雄激素。它是AR激动剂的黄金标准。

Features and Benefits

该化合物是受体分类及信号转导手册上核受体（类固醇）页面上的特色化合物。想要浏览手册的其他页面，请单击此处。

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

法规信息

新产品

此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies.

Nader Al Nakouzi et al.

European urology, 68(2), 228-235 (2014-05-20)

Cabazitaxel, abiraterone acetate (AA), and enzalutamide have been approved for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) following docetaxel chemotherapy. Whether taxanes and next-generation androgen receptor (AR) axis inhibitors are cross-resistant or not is a subject of

Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100.

Juliet Richards et al.

Cancer research, 72(9), 2176-2182 (2012-03-14)

Prostate cancer progression can be associated with androgen receptor (AR) mutations acquired following treatment with castration and/or an antiandrogen. Abiraterone, a rationally designed inhibitor of CYP17A1 recently approved for the treatment of docetaxel-treated castration-resistant prostate cancer (CRPC), is often effective

Cancer cell's neuroendocrine feature can be acquired through cell-cell fusion during cancer-neural stem cell interaction.

Liyuan Yin et al.

Scientific reports, 10(1), 1216-1216 (2020-01-29)

Advanced and therapy-resistant prostate tumors often display neural or neuroendocrine behavior. We assessed the consequences of prostate cancer cell interaction with neural cells, which are rich in the human prostate and resident of the prostate tumor. In 3-dimensional co-culture with

查看所有相关文献

全球贸易项目编号

货号	GTIN
R0908-10MG	04061836694098
R0908-50MG	04061832867755